Dimensional Fund Advisors LP Acquires 60,827 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Dimensional Fund Advisors LP raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,197,084 shares of the medical research company’s stock after purchasing an additional 60,827 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.66% of IQVIA worth $253,125,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc raised its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA during the 2nd quarter worth approximately $27,000. Rise Advisors LLC bought a new position in shares of IQVIA in the 1st quarter worth approximately $31,000. Riverview Trust Co bought a new stake in shares of IQVIA during the first quarter valued at approximately $32,000. Finally, International Assets Investment Management LLC purchased a new stake in IQVIA in the second quarter worth $32,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 1.1 %

Shares of NYSE:IQV opened at $242.67 on Thursday. The stock’s 50-day simple moving average is $239.74 and its two-hundred day simple moving average is $234.18. The stock has a market capitalization of $44.21 billion, a price-to-earnings ratio of 33.15, a PEG ratio of 2.24 and a beta of 1.49. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter last year, the firm posted $2.22 earnings per share. The firm’s revenue was up 2.3% compared to the same quarter last year. Analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their target price on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and cut their price objective for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Truist Financial lifted their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Evercore ISI boosted their target price on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $266.67.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.